Alliance Pharma ( (GB:APH) ) just unveiled an announcement.
Alliance Pharma PLC has announced the satisfaction of regulatory conditions for its acquisition by Aegros Bidco Limited, a company indirectly owned by DBAY Affiliates and the ERES IV Fund. This acquisition, to be executed through a Court-sanctioned scheme of arrangement, involves a final increased cash offer of 64.75 pence per share. With regulatory clearances from French and German authorities secured, the acquisition is on track, pending a Court sanction scheduled for May 2025. This move is expected to strengthen Alliance Pharma’s market position and provide a strategic advantage in the pharmaceutical sector.
More about Alliance Pharma
Alliance Pharma PLC operates in the pharmaceutical industry, focusing on the acquisition and licensing of pharmaceutical products. The company is known for its diverse portfolio of consumer healthcare and prescription medicines, catering to various market needs.
YTD Price Performance: 39.89%
Average Trading Volume: 6,380,326
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £347M
Find detailed analytics on APH stock on TipRanks’ Stock Analysis page.